US Clinical Trials Begin for Abbott's Remarkable Resorbable Stent
US-headquartered device manufacturer Abbott announced today the initiation of the Absorb III clinical trial in patients in the United States. This randomised, controlled trial is designed to enroll approximately 2,250 patients, the majority in the United States, and compare the performance of Abbott's drug eluting Absorb Bioresorbable Vascular Scaffold (BVS) device to the company's Xience family of drug eluting stents. The start of this trial in the United States follows the recent international commercial launch of Absorb in Europe and parts of Latin America and Asia, including the recent regulatory approval and launch in India, a country with a significant and growing prevalence of heart disease. Data from the Absorb III trial will support US regulatory filings for Absorb.
Absorb, a drug eluting, fully bioresorbable vascular scaffold1, is an innovative device for the treatment of coronary artery disease, which is a narrowing of one or more arteries that supply blood to the heart. Absorb is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures. Absorb works by opening a clogged vessel and restoring blood flow to the heart similar to a drug eluting metallic stent, the current standard of care. Absorb then dissolves into the blood vessel, leaving behind a treated vessel that may resume more natural function and movement because it is free of a permanent metallic implant.
Dean Kereiakes, MD, FACC, FSCAI, medical director of The Christ Hospital Heart & Vascular Center and the Lindner Research Center in Cincinnati, and professor of clinical medicine at Ohio State University, was one of the first physicians to enroll a patient into the Absorb III trial. "The deliverability of the Absorb device is impressive and similar to a best-in-class drug eluting stent," said Dr. Kereiakes, who is a co-primary investigator of the Absorb III trial. "Absorb combines the unique attributes of a dissolvable material with the established Multi-Link stent design, making the scaffold flexible and conformable to the vessel."
The Absorb III clinical trial is designed to evaluate potential benefits of Absorb in patients with coronary artery disease. Unlike a permanent metallic stent, preliminary evidence of natural vessel function suggests that treatment with an Absorb BVS could provide important clinical benefits.
"With the introduction of balloon angioplasty in the 1970s, cardiologists wanted to open a blocked vessel without leaving anything behind. Absorb represents the latest innovation that may help us reach this goal, which could result in important long-term benefits related to the restoration of natural vessel function," said Stephen Ellis, MD, section head of Interventional Cardiology at the Cleveland Clinic and co-primary investigator of the Absorb III trial. "The data collected on Absorb from the Absorb III trial could have the potential to drive significant changes in how cardiologists treat patients with coronary artery disease."
The primary endpoint of Absorb III is target lesion failure, a combined measure of safety and efficacy, at one year. In addition, a subset of patients within the trial will be evaluated for novel endpoints such as vasomotion, a measure of how much natural motion returns to the vessel as Absorb dissolves into the arterial tissue.
"Absorb is an excellent demonstration of Abbott's continued global leadership and innovation. The Absorb III trial will provide important insight about the benefits of Absorb in US patients with heart disease and will supplement the knowledge gained about this technology since the start of international clinical trials of Absorb in 2006," said Charles A Simonton, MD, FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "The advancement of Absorb into clinical trials in the United States represents an important step in the process of filing for US regulatory approval—with the goal of establishing Absorb as a new therapeutic option to treat US patients with heart disease, the number one killer of men and women."